Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd. on November 26, 2025, covering the month of November 2025. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital markets transaction rather than financial performance results.
Material Changes
The primary material event reported is the filing of a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (ADSs) available under the Company's At The Market Offering Agreement. Each ADS represents ten thousand (10,000) ordinary shares. The agreement was originally entered into with H.C. Wainwright & Co., LLC on February 3, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard incorporation of legal opinions. The document includes legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP, along with their consents, as exhibits.
Investor Verification Checklist
- Verify the specific increase in the maximum aggregate offering amount in the attached prospectus supplement.
- Review the terms of the At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
- Confirm the status of the Company's existing registration statements on Form S-8 and Form F-3 referenced in the filing.
- Check for subsequent filings regarding the actual issuance and sale of shares under the expanded program.